APO-CANDESARTAN TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CANDESARTAN CILEXETIL

Saadav alates:

APOTEX INC

ATC kood:

C09CA06

INN (Rahvusvaheline Nimetus):

CANDESARTAN

Annus:

8MG

Ravimvorm:

TABLET

Koostis:

CANDESARTAN CILEXETIL 8MG

Manustamisviis:

ORAL

Ühikuid pakis:

100/500

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0135220002; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2011-04-26

Toote omadused

_APO-CANDESARTAN Tablets Product Monograph_
Page 1 of 34
PRODUCT MONOGRAPH
PR
APO-CANDESARTAN
CANDESARTAN CILEXETIL TABLETS USP
4 MG, 8 MG, 16 MG AND 32 MG
ANGIOTENSIN II AT
1 RECEPTOR BLOCKER
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
JANUARY 29, 2019
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER: 222632
_APO-CANDESARTAN Tablets Product Monograph_
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 3
_SUMMARY PRODUCT INFORMATION
.................................................................................................
3_
_INDICATIONS AND CLINICAL USE
.......................................................................................................
3_
_CONTRAINDICATIONS
...........................................................................................................................
3_
_WARNINGS AND
PRECAUTIONS..........................................................................................................
4_
_ADVERSE REACTIONS
..........................................................................................................................
7_
_DRUG INTERACTIONS
.........................................................................................................................
13_
_DOSAGE AND ADMINISTRATION
.......................................................................................................
16_
_OVERDOSAGE
.....................................................................................................................................
18_
_ACTION AND CLINICAL PHARMACOLOGY
........................................................................................
18_
_STORAGE AND STABILITY
..................................................................................................................
21_
_DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................................
21_
PART II: SCIENTIFIC INFORMATION
..................